Fasting blood glucose to HDL-C ratio as a novel predictor of clinical outcomes in non-diabetic patients after PCI

Abstract

Background: This study was to assess the prognostic value of Fasting Blood Glucose to HDL-C Ratio (GHR) in non-diabetic patients with CAD undergoing PCI. Methods and Results: 6645 non-diabetic patients from two independent cohort the CORFCHD-PCI study (n=4282) and the CORFCHD-ZZ (n=2363) study were enrolled in Clinical Outcomes and Risk Factors of Patients with Coronary Heart Disease after PCI, Patients were divided into two groups according to the GHR value. The primary outcome included all-cause mortality (ACM) and cardiac mortality (CM). The average follow-up time was 36.51±22.50 months. We found that there were significant differences between the two groups in the incidences of ACM (P =0.013) and CM (P=0.038). Multivariate Cox regression analysis revealed GHR as an independent prognostic factor for ACM. The incidence of ACM increased 1.284 times in patients in the higher GHR group (hazard ratio [HR]:1.284 [95% confidence interval [CI]:1.010-1.631], P <0.05). Kaplan-Meier survival analysis suggested that patients with high GHR value tended to have an increased accumulated risk of ACM. However, we did not found significant differences in the incidence of major adverse cardiac events, main adverse cardiovascular and cerebrovascular events (MACCE), stroke, recurrent MI, bleeding events. Conclusions: This study indicates that GHR index is an independent and novel predictor of ACM in non-diabetic CAD patients who underwent PCI.

Fasting Blood Glucose to High-Density Lipoprotein Cholesterol Ratio in Relation to Short-Term Outcomes in Patients with Acute Coronary Syndrome

“…Therefore, in our study, we focused on the ACS population, regardless of whether they had diabetes. Our multivariate logistic regression analysis showed that an increased FG/HDL-C ratio was associated with MACEs and CV death, which is in agreement with the ndings of Guo et al (32). However, it is worth mentioning that further subgroup analyses in our study suggested that the ORs of patients with diabetes were less than those of patients with diabetes for MACEs, and the ORs of patients with diabetes were higher than those of patients with diabetes for CV death (MACEs, 1.08 vs 1.09; CV death, 1.11 vs. 1.10), although the interaction did not reach statistical signi cance.…”

“…Recently, the relationship between the FG/HDL-C ratio and clinical adverse outcomes was studied in patients without diabetes after PCI (32). The ndings suggested that the incidence of all-cause mortality increased by 28.4% in patients with a higher FG/HDL-C ratio (HR: 1.284; 95% CI, [1.010, 1.631]; P < 0.05).…”

The roles of fasting blood glucose to HDL-cholesterol ratio and monocyte to HDL-cholesterol ratio on coronary slow flow in non-diabetic patients

“…However, Kalayci et al [31] failed to show the relationship between CSF with HDL-C and attributed these contradictory findings to smoking, insufficient exercise time, and use of lipid-lowering drugs. GHR is a novel marker derived from the FBG and HDL-C, and one study showed that GHR may be an independent predictor for adverse cardiovascular outcomes in non-diabetic patients [13]. GHR may be considered as a marker indicating IR.…”

“…The previous studies demonstrated the relationship between CSF with high-density lipoprotein cholesterol (HDL-C) and triglyceride levels [11,12]. Recently, as a novel marker, the FBG/HDL-C ratio (GHR) has been reported as an independent predictor for all-cause mortality in non-diabetic patients undergoing percutaneous coronary intervention (PCI) [13]. To our best knowledge, the role of this novel marker in non-diabetic patients has not yet been investigated.…”

Association of fasting blood glucose to high-density lipoprotein cholesterol ratio with short-term outcomes in patients with acute coronary syndrome

“…However, whether the combined effect of the two indicators is greater than that of a single indicator has remained unclear. A recent study from 2020 has proven that the FG/HDL-C ratio is a novel indicator of adverse consequences in non-diabetic CAD patients who have undergone percutaneous coronary intervention (PCI) [ 14 ]. However, the FG/HDL-C ratio has not been validated in other populations.…”